伊立替康联合顺铂治疗小细胞肺癌60例临床观察  

The Clinical Observation of Combined Chemotherapy of Irinotecan and Cisplatin in the Treatment of 60 Case of Relapsed Advanced Small Cell Lung Cancer

作　　者：赵金波[1] 周金平[1] 刘芳[1] 李丹[1] 方丽萍[1] 乔京京[1] 孙秀华[1] 

机构地区：[1]大连医科大学附属二院肿瘤科,辽宁省大连市116023

出　　处：《中华全科医学》2011年第3期371-371,393,共2页Chinese Journal of General Practice

摘　　要：目的观察伊立替康(CPT-11)联合顺铂治疗复发晚期小细胞肺癌的疗效及安全性。方法伊立替康120～180 mg/m2静脉滴注d1,60～80 mg/m2静脉滴注d8;DDP 75 mg/m2静脉滴注d1～3;21 d为一周期。结果 60例均可评价疗效,完全缓解率8.3%(5/60),部分缓解率为40.0%(24/60),总有效率CR+PR为48.3%(29/60),稳定18例(30.0%);进展13例(21.7%)。主要毒副反应为血液学毒性和消化道症状,其中Ⅲ、Ⅳ度白细胞减少发生率为50.0%(30/60);血小板减少发生率为25.0%(15/60);Ⅲ度血小板减少发生率为3.3%(2/60);恶心呕吐发生率为80.0%(48/60),Ⅲ、Ⅳ度发生率为25%(15/60);腹泻发生率为50.0%(30/60),其中Ⅲ、Ⅳ度发生率为33.3%(20/60),全组无毒性相关死亡。结论伊立替康联合顺铂二线治疗复发晚期小细胞肺癌,有效率较高,毒副反应可以耐受。Objective The aim of this study was to evaluate the efficacy and safety of the irinotecan and cisplatin combination in relapsed advanced SCLC. Methods Eligible patients with SCLC who had progressed or relapsed after therapy were done with cisplatin and irinotecan. The regimen consisted of irinotecan 120 - 180 mg/m2 on d; and 60 -80 mg/m2 on d8 ,cisplatin 75 mg/ m2 on d1-3 ;the plan was given 21 days. Results In 60 evaluable patients,response include 5 complete remissions and 24 partial remissions（ overall response rate 48.3% ）. 18 patients had stable disease and 13 had progressive disease,the main toxicity was the matologieal toxicity, nausa and vomiting Grade III, IV leukopenia was seen in 30 patients （50.0%） , thrombocytopenia was seen in 15 patients（25.0% ） ;Nausea and vomiting was seen in 48 patients （80.0%） ;Grade m, rv nausea and vomiting was seen in 20 patients（25.0% ）, diarrhea was seen in 30 patients （50.0%）. There were no treatment-related death. Conclusion The eombination of irinoteean and eisplatin was highly aetive and tolerable in patients with relapsed SCLC when it was administered as seeond-line treatment.

关 键 词：伊立替康 顺铂 小细胞肺癌 联合化疗 

分 类 号：R734.2[医药卫生—肿瘤] R453[医药卫生—临床医学]